Propanc Biopharma reports preclinical PRP data in pancreatic cancer
Propanc Biopharma said its preclinical PRP package showed 90% tumor growth inhibition and more than 2.5-fold survival extension in advanced PDAC models.
Propanc Biopharma said its preclinical PRP package showed 90% tumor growth inhibition and more than 2.5-fold survival extension in advanced PDAC models.